DOI:
10.1055/s-00050348
Indian Journal of Medical and Paediatric Oncology
LinksClose Window
References
Schwartz GK, LoRusso pM, Dickson MA, Randolph SS, Shaik MN, Wilner KD. et al.
phase I study of pD 0332991, a cyclin-dependent kinase inhibitor, administered in 3-week cycles (Schedule 2/1).
Br J Cancer 2011;
104: 1862-8
Access:
Access:
We do not assume any responsibility for the contents of the web pages of other providers.